Abstract
HDL is the primary mediator of cholesterol mobilization from the periphery to the liver via reverse cholesterol transport (RCT). A critical first step in this process is the uptake of cholesterol from lipid-loaded macrophages by HDL, a function of HDL inversely associated with prevalent and incident cardiovascular disease. We hypothesized that the dynamic ability of HDL to undergo remodeling and exchange of apoA-I is an important and potentially rate-limiting aspect of RCT. In this study, we investigated the relationship between HDL-apoA-I exchange (HAE) and serum HDL cholesterol (HDL-C) efflux capacity. We compared HAE to the total and ABCA1-specific cholesterol efflux capacity of 77 subjects. We found that HAE was highly correlated with both total (r = 0.69, P < 0.0001) and ABCA1-specific (r = 0.47, P < 0.0001) efflux, and this relationship remained significant after adjustment for HDL-C or apoA-I. Multivariate models of sterol efflux capacity indicated that HAE accounted for approximately 25% of the model variance for both total and ABCA1-specific efflux. We conclude that the ability of HDL to exchange apoA-I and remodel, as measured by HAE, is a significant contributor to serum HDL efflux capacity, independent of HDL-C and apoA-I, indicating that HDL dynamics are an important factor in cholesterol efflux capacity and likely RCT.
Highlights
HDL is the primary mediator of cholesterol mobilization from the periphery to the liver via reverse cholesterol transport (RCT)
We investigated the relationship between HDL dynamics and cholesterol efflux capacity in human subjects
Our previous work indicated that the ability of HDL to remodel and/or exchange apoA-I is attenuated in CVD subjects with similar apoA-I and HDL cholesterol (HDL-C) levels, suggesting that direct measurement of HDL dynamics measures a HDL property distinct from apoA-I or cholesterol concentration [31]
Summary
HDL is the primary mediator of cholesterol mobilization from the periphery to the liver via reverse cholesterol transport (RCT). We investigated the relationship between HDL-apoA-I exchange (HAE) and serum HDL cholesterol (HDL-C) efflux capacity. The causal relationship between HDL-C level and reduced CVD risk has been questioned in light of human genetic variations that reduce HDL-C yet do not increase CVD risk, such as LCAT deficiency and apoA-IMilano [8, 9], and clinical studies of compounds that increase HDL-C but do not improve cardiovascular outcomes [10,11,12] These observations underscore the complexities of HDL and the importance of direct measurement of HDL function (biological activity), in particular, its ability to facilitate RCT. ApoA-I, the major protein component of HDL, plays a key role in RCT, and is integral to the interaction between HDL and the various receptors and HDL remodeling
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.